Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001989 · ClinicalTrials.gov registry record · Phase 2

A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin

A Phase 2 study of HIV Infections, sponsored by Genelabs Technologies.

Completed
Registry status
Phase 2
Development phase
8
Study locations

NCT00001989: Completed Phase 2 study of HIV Infections, sponsored by Genelabs Technologies.

NCT00001989 is a Phase 2 study of HIV Infections that has completed, run by Genelabs Technologies. The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001989, a Phase 2 study of HIV Infections, has completed, sponsored by Genelabs Technologies.

COMPLETED
Registry status
Phase 2
Development phase
8
Study locations

Study Summary

This study involves GLQ223 administration to patients who have not previously been exposed to it, but who have received at least 9 months of zidovudine therapy. Efficacy evaluations will include survival, opportunistic infections, T4 cell count, and assessments of viral load.

Conditions Studied

HIV Infections

Interventions

  • DRUG Zidovudine
  • DRUG Trichosanthin

Study Locations (8)

California

  • ViRx Inc - San Francisco
  • Dr Larry A Waites - San Francisco
  • Saint Francis Mem Hosp - San Francisco
  • UCSF - San Francisco Gen Hosp - San Francisco

Florida

  • Miami Veterans Administration Med Ctr - Miami
  • Infectious Disease Research Institute Inc - Tampa

Illinois

  • Northwestern Univ - Chicago

New York

  • Saint Vincent's Hosp and Med Ctr - New York

Trial Details

FieldValue
Phase Phase 2
Genelabs Technologies

2 total trials

What the finished NCT00001989 record still lists

NCT00001989 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Zidovudine is the first listed.

NCT00001989 lists 8 locations in 4 states (California, Florida, Illinois).

Frequently Asked Questions

What is clinical trial NCT00001989 about?

NCT00001989 is a clinical study titled "A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin". This study involves GLQ223 administration to patients who have not previously been exposed to it, but who have received at least 9 months of zidovudine therapy. Efficacy evaluations will include survival, opportunistic infections, T4 cell count, and assessments of viral load.

What is the current status of trial NCT00001989?

This trial is currently completed. It is a Phase 2 study.

What conditions does trial NCT00001989 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00001989?

The interventions under investigation include: Zidovudine (DRUG), Trichosanthin (DRUG).

Who is sponsoring clinical trial NCT00001989?

This trial is sponsored by Genelabs Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001989 being conducted?

This trial has 8 study locations across California, Florida, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00001989, the US trial registry maintained by the National Library of Medicine. NCT00001989 (unsized enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.